Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics entered an underwriting agreement for a public offering of 10,345,000 shares of common stock at $29.00 per share. The company expects gross proceeds of about $300 million and net proceeds of approximately $282 million, before any exercise of the underwriters’ option.
The underwriters have a 30-day option to buy up to an additional 1,551,750 shares at the same price, and the deal is expected to close on or about April 6, 2026, subject to customary conditions. Celldex plans to use the net proceeds, together with existing cash and investments, to support potential commercial launch of barzolvolimab for CSU in the United States if approved, further clinical and preclinical development of its pipeline, expansion of its bispecific antibody platform, additional pipeline programs, and general corporate purposes.
Celldex Therapeutics is offering shares of its common stock pursuant to a preliminary prospectus supplement. The supplement describes an at-the-market style shelf offering under the company’s existing registration and notes Nasdaq symbol CLDX with a last reported sale price of $31.72 per share on March 31, 2026.
The document discloses 66,549,442 shares outstanding as of December 31, 2025, outstanding options of 9,134,278 shares (weighted-average exercise price $26.49), and 2,753,587 shares reserved under equity plans. It states net tangible book value of $500.0 million or $7.51 per share as of December 31, 2025. The prospectus supplement leaves the offered share amount, offering price and estimated proceeds blank in the provided excerpt.
Celldex Therapeutics is offering shares of its common stock pursuant to a preliminary prospectus supplement. The supplement describes an at-the-market style shelf offering under the company’s existing registration and notes Nasdaq symbol CLDX with a last reported sale price of $31.72 per share on March 31, 2026.
The document discloses 66,549,442 shares outstanding as of December 31, 2025, outstanding options of 9,134,278 shares (weighted-average exercise price $26.49), and 2,753,587 shares reserved under equity plans. It states net tangible book value of $500.0 million or $7.51 per share as of December 31, 2025. The prospectus supplement leaves the offered share amount, offering price and estimated proceeds blank in the provided excerpt.
Celldex Therapeutics Inc ownership update: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned of Common Stock, representing 0% of the class, following an internal realignment effective January 12, 2026. The filing notes certain Vanguard subsidiaries now report separately.
Celldex Therapeutics amendment reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen beneficially owned 1,758,357 shares of common stock, representing 2.6% as of the close of business on December 31, 2025. The filing attributes shared voting and shared dispositive power of 1,758,357 shares to the reporting persons and notes Point72 entities act as investment manager and general partner. The statement clarifies these reporting persons hold no sole voting or dispositive power and provides their principal business address.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on mast cell biology, developing monoclonal and bispecific antibodies for severe inflammatory, allergic and autoimmune diseases. Its lead drug, barzolvolimab (CDX‑0159), targets the KIT receptor to inhibit and deplete mast cells, aiming to treat conditions where current therapies are inadequate.
Barzolvolimab has shown rapid, durable and clinically meaningful Phase 1/2 results in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), and is now in large global Phase 3 programs in CSU and Phase 3 in cold urticaria and symptomatic dermographism, plus Phase 2 trials in prurigo nodularis and atopic dermatitis. Celldex discontinued eosinophilic esophagitis after mast cell depletion did not translate into symptom benefit but is advancing CDX‑622, a bispecific targeting TSLP and SCF, through Phase 1. The company is scaling up commercial manufacturing, building its commercial organization, and relies on key licenses such as a Yale agreement for barzolvolimab, while operating in a highly competitive dermatology and immunology landscape. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was $1.3 billion, with 66,566,346 shares outstanding as of February 13, 2026.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on mast cell biology, developing monoclonal and bispecific antibodies for severe inflammatory, allergic and autoimmune diseases. Its lead drug, barzolvolimab (CDX‑0159), targets the KIT receptor to inhibit and deplete mast cells, aiming to treat conditions where current therapies are inadequate.
Barzolvolimab has shown rapid, durable and clinically meaningful Phase 1/2 results in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), and is now in large global Phase 3 programs in CSU and Phase 3 in cold urticaria and symptomatic dermographism, plus Phase 2 trials in prurigo nodularis and atopic dermatitis. Celldex discontinued eosinophilic esophagitis after mast cell depletion did not translate into symptom benefit but is advancing CDX‑622, a bispecific targeting TSLP and SCF, through Phase 1. The company is scaling up commercial manufacturing, building its commercial organization, and relies on key licenses such as a Yale agreement for barzolvolimab, while operating in a highly competitive dermatology and immunology landscape. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was $1.3 billion, with 66,566,346 shares outstanding as of February 13, 2026.
Celldex Therapeutics reported wider losses for the fourth quarter and full year 2025 as it accelerated investment in its immunology pipeline, led by barzolvolimab in chronic urticarias. Fourth quarter revenue was $0.1 million, while research and development expenses rose to $75.3 million and general and administrative costs to $11.9 million.
The company posted a fourth quarter net loss of $81.3 million, or ($1.22) per share, and a full-year 2025 net loss of $258.8 million, or ($3.90) per share. Cash, cash equivalents and marketable securities were $518.6 million as of December 31, 2025, and Celldex expects this to fund operations through 2027.
Operationally, Celldex completed enrollment in both Phase 3 chronic spontaneous urticaria studies six months ahead of guidance, with topline data expected in Q4 2026 and a planned BLA submission in 2027. Enrollment also finished in Phase 2 prurigo nodularis and atopic dermatitis trials, and the company advanced its bispecific antibody CDX-622 with ongoing Phase 1 studies, setting up multiple key data readouts in 2026.
Celldex Therapeutics reported wider losses for the fourth quarter and full year 2025 as it accelerated investment in its immunology pipeline, led by barzolvolimab in chronic urticarias. Fourth quarter revenue was $0.1 million, while research and development expenses rose to $75.3 million and general and administrative costs to $11.9 million.
The company posted a fourth quarter net loss of $81.3 million, or ($1.22) per share, and a full-year 2025 net loss of $258.8 million, or ($3.90) per share. Cash, cash equivalents and marketable securities were $518.6 million as of December 31, 2025, and Celldex expects this to fund operations through 2027.
Operationally, Celldex completed enrollment in both Phase 3 chronic spontaneous urticaria studies six months ahead of guidance, with topline data expected in Q4 2026 and a planned BLA submission in 2027. Enrollment also finished in Phase 2 prurigo nodularis and atopic dermatitis trials, and the company advanced its bispecific antibody CDX-622 with ongoing Phase 1 studies, setting up multiple key data readouts in 2026.
Celldex Therapeutics, Inc. shareholder Wellington Management Group LLP and affiliated entities report beneficial ownership of 8,079,608 shares of common stock, representing 12.16% of the class. The shares are held of record by clients of various Wellington investment advisers, including Vanguard Health Care Fund.
The Wellington entities report no sole voting or dispositive power and instead share voting and/or dispositive power over these shares through their advisory relationships. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Celldex.
State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Celldex Therapeutics, Inc. common stock. As of 12/31/2025, State Street reported beneficial ownership of 3,397,713 shares, representing 5.1% of Celldex’s outstanding common stock.
State Street reported shared voting power over 3,194,178 shares and shared dispositive power over 3,397,713 shares, with no sole voting or dispositive authority. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Celldex.
Celldex Therapeutics senior executive reports stock option exercises. A company officer serving as Senior Vice President and Chief Business Officer filed a Form 4 covering two option exercises in Celldex Therapeutics, Inc. common stock on 12/15/2025. The reporting person acquired 8,333 shares at an exercise price of $9.0165 per share and 11,000 shares at an exercise price of $2.78 per share through the exercise of incentive stock options.
Following these transactions, the officer beneficially owns 20,097 shares of Celldex common stock directly, which includes 764 shares acquired under the company’s 2004 Employee Stock Purchase Plan. After the exercises, one option grant for 8,333 shares expiring on 06/13/2028 remains partially outstanding with 5,000 derivative securities beneficially owned, while a second option grant for 11,000 shares expiring on 06/19/2029 has been fully exercised.
Celldex Therapeutics officer Freddy A. Jimenez reported selling 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025 at $29.095 per share. Following this sale, he directly owns 30,796 shares. The report identifies him as the company’s Senior Vice President and General Counsel and indicates the Form 4 was filed for a single reporting person.